VolitionRx Limited (VNRX)

Market Cap	65.79M
Revenue (ttm)	775,302
Net Income (ttm)	-35.32M
Shares Out	82.07M
EPS (ttm)	-0.50
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,760,251
Open	0.650
Previous Close	0.600
Day's Range	0.610 - 0.875
52-Week Range	0.550 - 2.100
Beta	1.35
Analysts	Strong Buy
Price Target	3.75 (+362.85%)
Earnings Date	May 8, 2024

About VNRX

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening blood test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early canc...

• Industry: Diagnostics & Research
• Sector: Healthcare
• CEO: Cameron Reynolds MBA
• Employees: 110
• Stock Exchange: NYSEAMERICAN
• Ticker Symbol: VNRX

Financial Performance

In 2023, VolitionRx's revenue was $775,302, an increase of 153.04% compared to the previous year's $306,392. Losses were -$35.32 million, 16.7% more than in 2022.

Analyst Forecast

According to 4 analysts, the average rating for VNRX stock is "Strong Buy." The 12-month stock price forecast is $3.75, which is an increase of 362.85% from the latest price.

Price Target

$3.75

(362.85% upside)

Analyst Consensus: Strong Buy